Are rotavirus vaccines a good investment for middle-income countries?

Middle-income countries not eligible for support from Gavi, the Vaccine Alliance, have been slow to introduce rotavirus vaccines, largely due to cost concerns. A PATH analysis shows that, in most cases, rotavirus vaccination is likely to be highly cost-effective and beneficial for these countries.

Brief is available in English, French, Russian, and Spanish.

Corporate author(s): PATH

Publication date: July 2021

Available materials

  1. English

    1. Are rotavirus vaccines a good investment for middle-income countries? 85 KB PDF

  2. French

    1. Les vaccins antirotavirus sont-ils un bon investissement pour les pays à revenu intermédiaire ? 73.5 KB PDF

  3. Russian

    1. Целесообразно ли странам со средним уровнем доходов инвестировать в вакцины от ротавирусных инфекций? 165.3 KB PDF

  4. Spanish

    1. ¿Las vacunas contra rotavirus son una buena inversión para países de ingresos medios? 73.3 KB PDF